Scientists have discovered a potential new drug that could help people with Alzheimer’s disease by improving memory and repairing brain damage. The drug, called GL-II-73, was tested on mice and showed promising results in restoring cognitive function.
This breakthrough study was conducted by researchers at the Centre for Addiction and Mental Health (CAMH) and published in Neurobiology of Aging.
Alzheimer’s disease is a serious condition that affects nearly 50 million people worldwide. It causes memory loss, confusion, and changes in behavior. As the disease progresses, it becomes harder for people to carry out daily activities. Despite years of research, there is no cure, and current treatments only provide temporary relief without stopping the disease from worsening.
For over a decade, Dr. Etienne Sibille and Dr. Thomas Prevot from CAMH have been studying how Alzheimer’s affects the brain. Their work has led to the discovery of GL-II-73, a drug that targets specific brain pathways linked to memory.
Unlike most Alzheimer’s treatments, which focus on reducing harmful beta-amyloid plaques in the brain, GL-II-73 works differently. It strengthens communication between brain cells by acting on GABA receptors in the hippocampus, an area important for learning and memory.
To test the drug, the scientists used mice that were genetically modified to develop symptoms of Alzheimer’s. These mice experience memory problems similar to those seen in human patients.
The researchers divided them into groups, some receiving a single dose of GL-II-73 and others undergoing a longer, four-week treatment. They also included normal mice for comparison.
The results were impressive. Younger mice with early-stage Alzheimer’s symptoms showed a significant improvement in memory after just one dose. They performed as well as healthy mice in memory tests.
Older mice with more advanced symptoms also benefited, though their improvements were not as dramatic. This suggests that GL-II-73 is most effective when given early in the disease but can still help in later stages by partially restoring memory and repairing brain cells.
One of the most exciting aspects of the study was that the drug helped grow and strengthen neural connections. This is crucial because Alzheimer’s disease gradually weakens the connections between brain cells, making it harder for people to think clearly and remember things.
The ability of GL-II-73 to repair these connections makes it different from current treatments, which only slow the symptoms rather than fix the underlying problem.
The researchers also believe that this drug might help with other brain disorders linked to memory loss, such as depression, epilepsy, and schizophrenia. Since these conditions also involve disruptions in brain signaling, GL-II-73 could offer hope for a wider range of patients beyond those with Alzheimer’s.
The success of this study has led to further developments. In 2019, CAMH helped launch Damona Pharmaceuticals, a company focused on turning this research into real treatments. With funding from major investors, Damona Pharmaceuticals has been working to prepare GL-II-73 for human trials.
In a major step forward, the drug recently received approval from the U.S. Food and Drug Administration (FDA) to begin testing on people. The first human clinical trial is expected to start in early 2025.
This study provides a glimpse of hope for Alzheimer’s patients and their families. While it is still early in the process, the ability of GL-II-73 to restore memory in mice suggests it could become a valuable treatment in the future.
More research is needed to confirm its safety and effectiveness in humans, but the progress so far is encouraging. If successful, this drug could change how Alzheimer’s is treated and offer millions of people a chance to regain lost memories and improve their quality of life.
If you care about Alzheimer’s, please read studies about Vitamin D deficiency linked to Alzheimer’s, vascular dementia, and Oral cannabis extract may help reduce Alzheimer’s symptoms.
For more information about brain health, please see recent studies about Vitamin B9 deficiency linked to higher dementia risk, and results showing flavonoid-rich foods could improve survival in Parkinson’s disease.
The research findings can be found in Neurobiology of Aging.
Copyright © 2025 Knowridge Science Report. All rights reserved.
